(ROS) production or reduced antioxidant capacity. A principle antioxidant pathway is regulated by the redox sensitive transcription factor, NF-E2 p45-related factor-2 (NRF2/NFE2L2). In unstressed cells, low levels of NRF2 are maintained through interaction with Kelch-like ECHassociated protein 1 (KEAP1), an adapter for the E3 ubiquitin ligase Cullin 3 (CUL3) that directs NRF2 for proteasomal degradation. 13 Modification of redox and electrophile sensitive cysteine residues inhibits the substrate adaptor activity of KEAP1 allowing NRF2 accumulation. The interaction of KEAP1 with NRF2 is further modulated by phosphorylation of NRF2 at serine 40 by protein kinase C (PKC).
Introduction
Chronic lymphocytic leukemia (CLL) with defective DNA damage response (DDR) is refractory to conventional chemotherapeutics. 1 The loss of DDR occurs through inactivation of ATM and TP53 genes. 2 ATM mutations appear in 13%-16% of CLLs and are distributed across a large coding region encompassing 64 exons. 3, 4 The loss of ATM function typically occurs through the combined effect of 11q deletion (monoalleic ATM loss) and an ATM mutation, biallelic ATM mutations, or less frequently due to the presence of a single mutation, capable of exerting dominant-negative effect on the remaining ATM allele. 3, 4 Compared to CLL tumors with 11q deletion only, those with inactivation of both ATM alleles exhibit abrogated DNA damage-induced apoptotic responses in vitro and rapid clonal expansion in vivo, leading to reduced overall and treatment-free survival. 1 Furthermore, in the phase III UK CLL4 trial that compared chlorambucil with fludarabine either alone or in combination with cyclophosphamide, CLL patients with biallelic ATM inactivation revealed progression-free survival inferior to tumors with a single mutation or 11q deletion, which was second only to tumors with loss/mutation of both TP53 alleles. 5 Early cytogenetic studies showed that CLL progression is associated with the emergence of 11q deleted subclones. 6 More recent reports of the dynamic nature of clonal progression has led to the understanding that the selective pressure imparted by DNA damaging agents favors the expansion of pre-existing subclones with defective DDR and consequently successive rounds of treatment with these agents are less effective. 7, 8 There is, therefore, a need for therapeutic strategies that act independently of the DDR pathway that can target ATM-null CLL cells.
ATM is a serine/threonine protein kinase activated by DNA double strand breaks (DSBs) that co-ordinates the activation of cell cycle checkpoints, DNA repair and p53-dependent apoptosis. 9 ATM phosphorylates numerous substrates and is involved in the regulation of a wide range of cellular processes. Consequently, deficiencies in any of these processes caused by the loss of ATM could be used as therapeutic targets. 10, 11 Consistent with this notion, ATM-null CLL cells are defective in homologous recombination repair (HRR), a deficiency that can be exploited to induce tumorspecific killing via enhanced requirement for HRR upon PARP-inhibition. 11 ATM is also implicated in redox homeostasis. 12 Deregulation of redox homeostasis results in oxidative stress and occurs either due to increased reactive oxygen species Inactivation of the Ataxia Telangiectasia Mutated gene in chronic lymphocytic leukemia results in resistance to p53-dependent apoptosis and inferior responses to treatment with DNA damaging agents. Hence, p53-independent strategies are required to target Ataxia Telangiectasia Mutated-deficient chronic lymphocytic leukemia. As Ataxia Telangiectasia Mutated has been implicated in redox homeostasis, we investigated the effect of the Ataxia Telangiectasia Mutated-null chronic lymphocytic leukemia genotype on cellular responses to oxidative stress with a view to therapeutic targeting. We found that in comparison to Ataxia Telangiectasia Mutated-wild type chronic lymphocytic leukemia, pro-oxidant treatment of Ataxia Telangiectasia Mutated-null cells led to reduced binding of NF-E2 p45-related factor-2 to antioxidant response elements and thus decreased expression of target genes. Furthermore, Ataxia Telangiectasia Mutated-null chronic lymphocytic leukemia cells contained lower levels of antioxidants and elevated mitochondrial reactive oxygen species. Consequently, Ataxia Telangiectasia Mutatednull chronic lymphocytic leukemia, but not tumors with 11q deletion or TP53 mutations, exhibited differentially increased sensitivity to pro-oxidants both in vitro and in vivo. We found that cell death was mediated by a p53-and caspase-independent mechanism associated with apoptosis inducing factor activity. Together, these data suggest that defective redox-homeostasis represents an attractive therapeutic target for Ataxia Telangiectasia Mutated-null chronic lymphocytic leukemia. 13 Modification of redox and electrophile sensitive cysteine residues inhibits the substrate adaptor activity of KEAP1 allowing NRF2 accumulation. The interaction of KEAP1 with NRF2 is further modulated by phosphorylation of NRF2 at serine 40 by protein kinase C (PKC).
14 Within the nucleus, NRF2 forms heterodimers with v-maf musculoaponeurotic fibrosarcoma oncogene homolog (MAF) proteins (MAF-F, G and K) and binds to antioxidant response elements (AREs) in the promoters of target genes such as those required for glutathione synthesis and its own promoter. 15 This activity is regulated by the transcriptional repressor BTB and CNC homology 1 transcription factor (BACH1) which competes for the MAF binding partners and for binding to gene promoters. 16 In addition, genetic models suggest that binding of Nrf-2 and its activity are regulated by the ATM substrate, Brca1. 17 The most compelling evidence for the role of ATM in redox homeostasis comes from studies of the human radiosensitivity syndrome, Ataxia Telangiectasia (A-T), where both ATM alleles are inactivated. Cells from these patients display increased oxidative stress as a consequence of elevated levels of ROS, increased oxidized/reduced glutathione (GSSG/GSH) ratio, diminished capacity to scavenge ROS and mitochondrial dysfunction. 12, 18 Furthermore, ATM is directly activated by oxidative stress 19 and can exert antioxidant activity through regulation of the pentose-phosphate pathway. 20 Recent evidence suggests that ATM might regulate oxidative stress through NRF2. Namely, Nrf2 target gene expression was decreased in Atm-/-murine osteoblasts and this was rescued by the ectopic expression of PKC delta (PKCδ). 21 In this study, we tested the hypothesis that ATM-null CLLs have an intrinsic defect in their antioxidant defenses that might be exploited to induce synthetic lethality of tumor cells by escalating oxidative stress. We show that compared to ATM-wild type (wt) CLL, ATM-null CLL tumors exhibited defective NRF2-dependent antioxidant transcriptional responses, decreased antioxidant capacity, elevated mitochondrial ROS, and increased sensitivity to pro-oxidants both in vitro and in vivo. Furthermore, we demonstrate that pro-oxidant treatment bypassed the need for a functional DRR and induced cell death via a p53-and caspase-independent mechanism involving apoptosis inducing factor (AIF).
Methods

Patients' samples and cell lines
Chronic lymphocytic leukemia samples were obtained from Birmingham and Bournemouth Hospitals (Online Supplementary  Table S1 ). These were comprised of 3 CLLs with monoallelic ATM loss, 1 monoallelic ATM mutant, 3 biallelic ATM mutants, 5 with combined ATM mutation/deletion and 3 CLLs with TP53 mutations. All patients' samples contained more than 90% tumor cells. South Birmingham Ethics Committee granted approval for the study. CII, HG3 and PGA isogenic CLL cell lines expressing short hairpin (sh)-RNA against GFP or ATM were generated as previously described. 
Quantitative real-time PCR
SYBR-Green quantitative real-time PCR (Q-PCR) (Life Technologies) was applied with primers against NRF2, NQO1, GCLM, GSR and HMOX1 (Online Supplementary Appendix). Primers against β-ACTIN were used for normalization and quantification was achieved using the comparative Ct method.
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XChIP
XChIP was applied to primary CLL samples before and after treatment with 100 mM tBHQ for 6 h using anti-NRF2 and preimmune antisera as previously described 23 (Online Supplementary Appendix).
Biochemical assays
GSH was quantified using a Glutathione Assay Kit (SigmaAldrich). To determine GSSG, GSH was first derivatized with N-ethylmaleimide (Sigma-Aldrich). Levels of NADPH and NADP + were quantified using an NADP/NADPH assay kit (Abcam, Cambridge, UK).
Mitochondrial ROS assay
Mitochondrial superoxide was detected using MitoSox Red (Life Technologies) in accordance with the manufacturer's instructions and quantified using an LSR II flow cytometer (BD Biosciences, Oxford, UK) (Online Supplementary Appendix).
RNA knockdown
Knockdown of gene expression in HaCat cells was achieved by transfection of siRNAs against ATM, KEAP1, BRCA1 or Scrambled siRNA with Oligofectamine (Life Technologies) in accordance with the manufacturer's instructions (Online Supplementary Appendix and Online Supplementary Table S4 ).
Immunoblotting
Immunoblotting was performed as previously described 24 (Online Supplementary Appendix).
Murine xenograft
Animals were treated in accordance with United Kingdom Home Office guidelines, Schedule 1. Subcutaneous tumors were initiated by injection of 5x10 6 CII-isogenic cell lines with and without stable ATM-knockdown into 6-week old NOD.CgPrkdc scid Il2rg tm1Wjl /SzJ (NSG) mice. Tumors were grown for 15 days prior to treatment with 6 mg/kg parthenolide or vehicle via intra-peritoneal injection for 5 days.
Primary CLL tumor cells were engrafted as previously described. 25 Briefly, 6-week old NSG mice were sublethally irradiated (1.25 Gy) prior to intravenous co-injection of 50x10 6 PBMC from an ATM-null CLL patient and 10x10 3 CD14 + mono-cytes from a healthy donor. After three days, mice were randomized and treated with a daily dose of either 100 mg/kg DMAPT-HCl or vehicle by oral gavage for nine days. Splenic tumor burden was assessed by FACS analysis.
Statistical analysis
In vitro and in vivo data were analyzed using paired or unpaired 2-tailed Student's t-tests. Data are presented as ± standard error of the mean (SEM). haematologica | 2015; 100(8) Mitochondrial superoxide impaired in ATM-null CLLs (n=4) ( Figure 1A) . Examination of previously generated expression data supported this observation. 26 Following exposure to IR, an insult that generates ROS, upregulation of 40 NRF2 regulated transcripts was significantly (P<0.05) impaired in ATM-null CLLs (n=6) compared to ATM-wt CLLs (n=5) (Online Supplementary Figure S4A) .
To investigate a possible role for KEAP1 in the defective induction of NRF2 target genes in ATM-null CLL, KEAP1 activity was inhibited pharmacologically or by siRNA knockdown. Tumor cells were treated with tBHQ, the quinone radical of which is an electrophile that covalently modifies cysteine residues in KEAP1 preventing it from targeting NRF2 for degradation. In ATM-wt tumors (n=5), high-dose tBHQ (100 mM) induced a 5-71 fold upregulation of NRF2 target genes ( Figure 1B) . In comparison, significantly lower expression (0.5-4.3 fold) was induced in ATM-null tumors (n=5). A similar differential was observed with low-dose tBHQ (10 µM) indicating that the defective expression in ATM-null CLLs was not due to toxicity (Online Supplementary Figure S4B) .
In accordance with a previous report, knockdown of KEAP1 also induced the expression of NRF2 target genes. 27 Inhibition of ATM function by siRNA-knockdown (n=3) ( Figure 1C ) or ATM-inhibitor (n=3) ( Figure  1D ) abolished induction of NRF2-target genes. These data indicated that the defective regulation of NRF2 transcripts in ATM deficient cells occurs downstream of KEAP1 function.
Consistent with an absence of a defect in the regulation of NRF2 by KEAP1 the expression of NRF2 mRNA and protein was comparable in ATM-wt and ATM-null tumors (Online Supplementary Figure S4C and D) . Following treatment with tBHQ, no difference was observed between ATM-wt and ATM-null CLLs regarding the change in levels of NRF2 or other proteins involved in this antioxidant pathway: KEAP1, BACH1 and MAF protein (Online Supplementary Figure S4D-F) .
A previous study suggested that ATM regulates NRF2 through PKCδ. 21 However, in keeping with the data from a proteomic study of ATM substrates, 10 we found no interaction between ATM and NRF2 in co-immunoprecipitation assay (Online Supplementary Figure S5A) . Furthermore, we did not detect an interaction between ATM and PKCδ and loss of ATM did not alter the levels of PKCδ or the levels of phosphorylated-serine on NRF2 (Online Supplementary Figure S5B and C) .
Brca1 was previously found to regulate Nrf-2 transcriptional activity. 17 Therefore, we next investigated the possibility that ATM co-operates with BRCA1 in the regulation of NRF2 activity. We found reduced induction of antioxidant genes in cells treated with either ATM or BRCA1-specific siRNAs ( Figure 1F and G). This defect was not increased by the combined knockdown of both genes, suggesting ATM and BRCA1 may act in the same pathway that regulates NRF2 function.
These data suggest that in CLL cells, loss of ATM-function induces a defect in NRF2 regulated gene expression that is independent of PKCδ, KEAP1, BACH1 and MAF proteins and may involve co-operation with BRCA1.
ATM-loss reduces binding of NRF2 to antioxidant response elements
In the absence of any defect in the regulation of NRF2 protein levels, we considered whether the transcriptional deregulation in ATM-null CLL tumors arises at the point of NRF2 binding to AREs. We used XChIP and Q-PCR to measure tBHQ-induced binding of NRF2 to an ARE in the promoter region of the prototypic NRF2 target gene NQO1. Consistent with the observed difference in gene A. Agathanggelou et al. 1080 haematologica | 2015; 100(8) Subcutaneous xenografts of ATMshRNA (n=7) and GFPshRNA (n=7) expressing CII-isogeneic cell lines were treated with 6 mg/kg parthenolide or vehicle by intraperitoneal injection for five days leading to a significant reduction in tumor volume. Tumor volume was calculated using the formula Vol = 0.5 x L x W 2 before and after treatment. (B) Xenografts of ATM-null primary chronic lymphocytic leukemia were established and treated by oral gavage with vehicle (n=5) or 100 mg/kg dimethylaminoparthenolide (DMAPT) (n=5) for nine days, leading to a significant reduced splenic tumor burden in DMAPT-treated animals, as determined by flow cytometry using antibodies against hCD19 (cl.HIB19), hCD3 (cl.SK7), hCD45 (cl.2D1) and mCD45 (cl.30-F11) (eBioscience Inc., San Diego, CA, USA) and CountBright absolute counting beads (Life Technologies). (C) Histological sections depicting differentially increased splenic 8-oxodG expression in DMAPT treated xenografts. Brown labeling indicates immobilization of anti-hCD19 (eBioscience) and anti-8-oxo-dG (Abcam) antibodies. Nuclei were counterstained blue with Hematocylin and images were captured at 200x magnification. Statistical significance was determined using Student's t-test. *P<0.05 was considered significant. Error bars represent SEM. reduced the generation of ∼50kb DNA fragments in H 2 O 2 -treated primary CLL tumors. Agarose plugs containing cells treated as indicated were subjected to pulsed field gel electrophoresis as described 32 and the separated DNA was visualized with ethidium bromide. The statistical significance was determined using Student's t-test. *P<0.05 was considered significant. Error bars represent SEM. induction, significantly less NRF2 bound to the promoter region of NQO1 in ATM-null CLL compared to wild-type tumors ( Figure 1E ). This suggests that the reduced NRF2 dependent transcription in ATM-null primary CLL cells is caused by defective binding of NRF2 to AREs.
ATM-null CLL cells exhibit reduced antioxidant capacity, elevated mitochondrial superoxide and increased sensitivity to pro-oxidants
In agreement with the effect on antioxidant transcriptional responses, the level of total cellular glutathione was significantly lower in ATM-null compared to ATM-wt primary CLL (Figure 2A ). This effect was recapitulated in three isogenic CLL cell lines with stable knockdown of ATM (Online Supplementary Figure S6A) .
The regeneration of GSH from GSSG is catalyzed by glutathione reductase (GSR) utilizing NADPH as a co-factor. In ATM-wt tumors, virtually all glutathione was in the reduced form (GSH) whereas in ATM-null tumors only 70% was reduced and 30% was oxidized (GSSG), indicating increased oxidative stress in these cells ( Figure  2B ). Accordingly, the pool of NADP + was significantly elevated in ATM-null compared to ATM-wt CLLs ( Figure  2C) .
A-T cells display continuous oxidative stress due to intrinsic mitochondrial dysfunction and contain elevated superoxide levels. 28 To determine whether ATM-null CLL cells share this phenotype, the levels of mitochondrial ROS were examined using the mitochondrial superoxide sensitive dye, MitoSox Red. Consistent with observations in A-T cells, mitochondrial ROS levels were significantly higher in ATM-null (n=3) than wild-type CLLs (n=3) (P=0.007) ( Figure 2D and E) .
Increased mitochondrial ROS damages the organelle promoting further dysfunction in a positive-feedback loop. 28 To test whether this occurs in ATM-null CLLs, tumors were exposed to extracellular ROS. H 2 O 2 induced significantly higher levels of mitochondrial superoxide in ATM-null CLLs (n=3) compared to wild-type CLLs (n=3) at all concentrations tested ( Figure 2E ). This suggests that the intrinsic mitochondrial dysfunction associated with ATM-deficiency can be further exacerbated using exogenous sources of ROS. Examination of mitochondrial DNA content showed that both ATM-null and ATM-wt CLL contained a comparable number of mitochondria but significantly more than PBMCs from normal donors (Online Supplementary Figure S6B) indicating that the increased mitochondrial ROS in ATM-null CLL is the result of mitochondrial dysfunction rather than mitochondrial number.
These data suggest that ATM-null CLL cells are under greater oxidative stress than their wild-type counterparts.
ATM-null CLL cells show increased sensitivity to pro-oxidants in vitro and in vivo
In view of the increased oxidative stress in ATM-null CLL cells, we determined if this translated to increased sensitivity to pro-oxidant treatment. ATM-null CLLs (n=6) were significantly more sensitive to H 2 O 2 than ATM-wt CLLs (n=9) in vitro ( Figure 2F ). The effect of ATM-deficiency on H 2 O 2 -sensitivity was confirmed in a CII-isogenic cell line with stable knockdown of ATM (Online Supplementary Figure S7A) .
Next, we addressed the sensitivity of ATM-null and wild-type primary CLLs to NAPQI and parthenolide, prooxidants that induce oxidative stress by depleting glutathione (GSH). 29, 30 ATM-null tumors were significantly more sensitive than wild-type to both reagents ( Figure 2G and 2H). The effects of H 2 O 2 , NAPQI and parthenolide were associated with oxidative damage, as treatment with N-acetyl cysteine (NAC), a glutathione precursor, protected cells (Online Supplementary Figure S7B-D) . Importantly, the tumor-specific activity of both H 2 O 2 and parthenolide was confirmed using PBMCs from normal donors (Online Supplementary Figure S7E and F) .
To determine if the increased sensitivity to pro-oxidants was specific to the ATM-null status, we examined primary CLL cells with monoallelic 11q deletion or TP53 mutations. The sensitivity of CLLs with either genotype did not significantly deviate from wild-type CLLs, suggesting that increased sensitivity to pro-oxidants is specifically associated with the ATM functional loss (Online Supplementary Figure S7G and H) .
The in vivo efficacy of pro-oxidant therapy on ATMdeficient CLL was examined using two murine xenograft models. First, a subcutaneous xenograft model of CII-isogenic cell lines with and without stable ATM-knockdown was established. Parthenolide significantly inhibited the growth of ATM-knockdown tumors compared to either vehicle treated cells or to parthenolide treated wild-type tumors (44.0% vs. 9.7%) ( Figure 3A) .
Finally, an ATM-null primary CLL xenograft was established, and for systemic pro-oxidant treatment, dimethylamino parthenolide-hydrochloride (DMAPT-HCl), a water-soluble and orally bioavailable form of parthenolide, 31 was generated. Quantification of engrafted splenic CLL cells demonstrated that pro-oxidant therapy significantly reduced hCD19 + tumor cell burden (P<0.05) ( Figure  3B ). Furthermore, engrafted cells displayed increased levels of 8-oxo-dG, indicating oxidative stress was induced following pro-oxidant treatment ( Figure 3C ).
These data show that pro-oxidant based therapies are effective against chemoresistant ATM-null CLL tumors in vitro and in vivo.
Pro-oxidant induced cell death in CLL is p53/caspase-independent and involves AIF
Since the DDR is defective in ATM-null CLL, a DDRindependent pathway must be operating to facilitate prooxidant induced cell death. Consistent with this, activation of the DDR was not detected in either ATM-null or wild-type CLL cells following treatment with therapeutically effective concentrations of H 2 O 2 (Online Supplementary Figure S8) , NAPQI or parthenolide (data not shown). To elucidate the mechanism of cell death induced by pro-oxidants, ATM-null primary CLL tumors were treated with NAPQI or H 2 O 2 with and without pan-caspase inhibitor. Caspase inhibition did not significantly affect NAPQI or H 2 O 2 -induced cell death of ATM-null primary CLL tumors ( Figure 4A and B) . This was confirmed by immunoblotting in CII-isogenic cell lines which showed that, in contrast to ionising radiation, PARP1-cleavage was not induced by NAPQI ( Figure 4C) .
Next, we investigated the induction of cell death by an alternative mechanism involving the cellular redistribution of AIF. In response to stress, AIF is released from the mitochondria as a cleaved 57kDa pro-apoptotic protein (tAIF) that translocates to the nucleus where it co-operates with endonuclease G to cause large-scale DNA fragmentation and chromatin condensation. 33 In untreated cells, AIF staining co-localized with mitochondria ( Figure 4D ), whereas treatment with H 2 O 2 led to nuclear translocation ( Figure 4E and F) . In agreement with the differential sensitivity of ATM-null CLL tumors to pro-oxidants, nuclear tAIF was induced with 10 mM H 2 O 2 , whereas in ATM-wt CLLs, 40 mM H 2 O 2 was required to elicit the same effect ( Figure 4F ). Inhibition of AIF prevented H 2 O 2 -induced digestion of genomic DNA into ∼50kb fragments, thus confirming the role of AIF in this process ( Figure 4G ).
These data demonstrate that pro-oxidants induce p53 and caspase-independent cell death in wild-type and ATM-null CLL associated with nuclear translocation of AIF.
Discussion
We show that the ATM-null phenotype in CLL can be targeted with pro-oxidant based therapies to induce selective killing. We demonstrate that a defect in the NRF2-directed antioxidant response is present in ATM-null primary CLLs. This correlated with reduced antioxidant capacity, increased mitochondrial ROS and increased sensitivity to pro-oxidants in vitro and in vivo. Previous reports have demonstrated increased sensitivity of CLL cells to pro-oxidant based therapies compared to nontumor cells, but this is the first study to demonstrate that this approach specifically targets the ATM-null phenotype in CLL. 34, 35 Our data suggest that binding of NRF2 to target gene AREs is reduced in ATM-null CLL despite normal levels of NRF2, KEAP1, BACH1 and MAF proteins and normal levels of NRF2/MAF heterodimerization. Previous studies indicated that reduced PKCδ levels might contribute to defective Nrf-2 regulation in Atm-/-mice and that NRF2 stability is regulated by phosphorylation at ser40 by PKC.
14, 21 We observed that PKCδ and serine-phosphorylated NRF2 levels are unaffected by the loss of ATM in CLL cells and that in agreement with previous proteomic screen, 10 both PKCδ and NRF2 are unlikely to be ATM substrates. In search for the mechanism of reduced NRF2 activity in ATM null cells, we confirmed the role of BRCA1 in the regulation of the NRF2 antioxidant response. Furthermore, by showing that the combined knockdown of ATM and BRCA1 does not cause further deregulation, we demonstrate that ATM and BRCA1 function in the same pathway to regulate NRF2-antioxidant responses. Previously, we have reported that ATMnull tumors are refractory to conventional DNA damaging therapies due to inactivation of the p53-dependent apoptosis pathway, 1, 36 underscoring the need for a p53-independent strategy for the treatment of these tumors. In this study, we found that ATM-null cells are differentially sensitive to pro-oxidants as reflected by the appearance of tAIF in the nuclei of these cells at lower concentrations of H 2 O 2 than in ATM-wt cells. The higher level of mitochondrial superoxide in ATM-null CLLs indicated mitochondrial dysfunction. Pro-oxidant treatment is likely to further damage the mitochondria, thus triggering the translocation of AIF and p53-independent cell death. Recent studies also suggest AIF translocation may occur due to an increase in inducible nitric oxide synthase (iNOS) activity following stimulation of JNK by ROS and the subsequent activation of ERK1/2. 37 In addition, ROS can induce the caspase-independent activation of the BH3 interacting domain death agonist (BID), thus leading to AIF translocation. 38 Most importantly, using a pro-oxidant based strategy, we show that ATM-null CLL cells are significantly more sensitive than ATM-wt tumors and non-tumor cells to agents previously shown to stimulate NRF2-mediated adaptation to stress. 39, 40 Thus both NAPQI and parthenolide represent novel clinically applicable approaches for the treatment of ATM-null CLL. Of note, acetaminophen, the NAPQI precursor, has previously been used in a phase I trial for the treatment of metastatic melanoma 41 as an approach to enhance the specificity of anti-cancer agents which deplete glutathione. Similarly, parthenolide and its water soluble derivative, DMAPT, have been shown to have activity against hematopoietic malignancies, including chemo-refractory CLL and acute myeloid leukemia. 42, 43 Targeting oxidative stress to bypass the defect in p53-dependent apoptosis is an attractive therapeutic strategy for several reasons. First, genetic variations present a challenging problem with respect to the treatment of CLL 8, 44 and elevated oxidative stress can impact on disease progression by inducing oxidative DNA damage 45 and increasing the mutation rate that supports clonal diversity. Indeed, in CLL, oxidative stress is present early in the genesis of disease and is detectable at the stage of premalignant monoclonal B-lymphocytosis. 46 Thus to avoid the selection of adverse subclones with ATM-deficiency that occurs with conventional genotoxic agents, 7, 8 it is preferable to target stress phenotypes common to all tumor cells and, as in this case, potential mechanisms of diversification. 47 Furthermore, elevated oxidative stress may provide a selective advantage for ATM-null CLL cells regarding their interactions with immune cells within lymphoid tissues. The activity of surrounding immune cells is suppressed by ROS and, therefore, loss of ATM and the associated increase in ROS production may facilitate immune evasion. 48 Finally, loss of ATM and the associated decrease in antioxidant levels may render the tumor cells more dependent on stromal cells for redox support, 49 thus providing a rationale for combined therapeutic approaches with pro-oxidants and inhibitors of tumor/microenvironment interactions.
Recently a number of p53-indendent treatments for CLL became available. These include use of immunomodulatory agents as well as inhibitors of B-cell receptor signaling that target either Bruton tyrosine kinase (ibrutininb) or PI3 kinase delta (idelalisib). 50 Prooxidant based therapies utilize oxidative stress as a cellular weakness of leukemic cells and represent an example of a synthetic lethality approach. It will be of interest to determine whether pro-oxidants could be used in combination with new targeted treatments to increase the benefit for patients with the ATM-null CLL phenotype.
Finally, it is important to note that the roles in DDR and oxidative stress responses denote two separate ATM functions. ATM is activated by oxidation of the cysteine residue at position 2991 in the FATC domain leading to formation of disulphide cross-linked dimers. 19 ATM mutated at C2991 is unresponsive to oxidative stress despite normal response to DNA damage. This raises the possibility that certain ATM mutations may not affect DDR and still render a phenotype amenable for targeting by pro-oxidants.
In summary, we show that the oxidative stress pheno-type is a valid therapeutic target in the treatment of ATMnull CLL due to the intrinsic deficiencies in redox homeostasis. Significantly, this mode of therapy bypasses the DDR defect found in ATM-null CLL cells and therefore represents a feasible approach for treatment of patients that harbor these subclones.
